`
`David L. Cavanaugh
`Reg. No. 36,476
`Owen K. Allen
`Reg. No. 71,118
`Robert J. Gunther, Jr.
`Pro Hac Vice to be filed
`Wilmer Cutler Pickering
`Hale and Dorr LLP
`1875 Pennsylvania Ave., NW
`Washington, DC 20006
`
`Adam R. Brausa
`Reg. No. 60,287
`Daralyn J. Durie
`Pro Hac Vice to be filed
`Durie Tangri LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________________________________________
`
`MYLAN PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`____________________________________________
`
`Cases IPR2016-01693
`Patent 6,407,213
`____________________________________________
`
`DECLARATION OF JOHN RIDGWAY BRADY
`
`Mylan v. Genentech
`IPR2016-01693
`Genentech Exhibit 2018
`
`
`
`IPR2016-01693
`Declaration of John Ridgway Brady
`
`I, John Ridgway Brady, declare as follows:
`
`I.
`
`Background
`
`1.
`
`I am a research technician employed by Genentech, Inc. for the past
`
`29 years. During that time, I have performed research in a number of areas
`
`including cell culture and cell line development, protein engineering, and bio-
`
`oncology.
`
`2.
`
`In 1984, I obtained my Bachelors of Science degree in cell biology
`
`from the University of California, Santa Barbara. In 1987, I began working for
`
`Genentech, and I am currently a senior research associate.
`
`3.
`
`In the late 1980s to early 1990s, I worked in the Cell Genetics
`
`Department in the laboratory of Cornelia Gorman, Ph.D., conducting experiments
`
`on plasmid construction and expression of proteins in mammalian cell lines.
`
`4.
`
`During my tenure with Dr. Gorman, I conducted numerous
`
`experiments at the direction of Drs. Gorman and Paul Carter to express various
`
`humanized 4D5 antibodies in the adenovirus-transformed human embryonic
`
`kidney cell line 293.
`
`5.
`
`In particular, Dr. Carter provided me with vectors containing the DNA
`
`encoding for different versions of the humanized 4D5 heavy and light chains, and
`
`directed me to produce an assortment of humanized 4D5 antibodies by using
`
`combinations of the various heavy and light chains. Per these directions, I
`
`- 1 -
`
`
`
`IPR2016-01693
`Declaration of John Ridgway Brady
`
`expressed and purified different humanized variants of the 4D5 antibody, and then
`
`provided them for assay analyses to determine binding affinity to HER2 and an
`
`ability to prevent proliferation in the SK-BR-3 cell line. I also developed stable
`
`cell lines that expressed certain humanized 4D5 antibodies. This work is included
`
`in the research paper, “Humanization of the anti-p185 antibody for human cancer
`
`therapy,” published in Proc. Nat’l. Acad. Sci., Vol. 89, pp. 4285-4289, May 1992,
`
`which I co-authored.
`
`6.
`
`The purpose of this work was to develop a humanized 4D5 antibody
`
`for use as a human therapeutic to treat cancers overexpressing p185HER2. Our work
`
`led to Herceptin®, which is used to treat certain breast and gastric cancers.
`
`7.
`
`As described below,
`
`, I had expressed six humanized
`
`4D5 antibodies with different combinations of humanized heavy and light chains
`
`and provided them for assay analysis, which showed that each of these variants had
`
`binding affinity to HER2.
`
`II. My Laboratory Notebooks
`
`8.
`
`My work on humanized 4D5 antibodies is documented in laboratory
`
`notebooks that I maintained. Genentech’s library issued laboratory notebooks to
`
`researchers to document their experiments, and each notebook had a unique
`
`number.
`
`- 2 -
`
`
`
`IPR2016-01693
`Declaration of John Ridgway Brady
`
`9.
`
`Attached to this declaration as Exhibit 2005 is my Notebook 10840,1
`
`which Genentech’s library issued to me on
`
`. I used Notebook
`
`10840 to detail experiments that I conducted from
`
` to
`
`, relating to the construction of plasmids, and in particular,
`
`creating plasmids to express humanized 4D5 antibodies.
`
`10. Attached to this declaration as Exhibit 2006 is my Notebook 11162,
`
`which was issued to me on
`
`. Notebook 11162 details
`
`experiments that I conducted from
`
`,
`
`relating to the transfection of cell lines and assay testing.
`
`11. As a Genentech researcher, I am expected to maintain a record of my
`
`experiments in my laboratory notebooks. Consistent with this expectation, I
`
`recorded the experiments I was doing in real time, providing the date of the
`
`experiment at the top left-hand corner of the page, followed by a brief description
`
`of the protocol and results. After an experiment was completed, I further dated and
`
`signed the page in the lower right-hand corner, and obtained the signature of a
`
`1
`
`Notebooks 10840 and 11162 were issued under the name John Ridgway,
`
`which was my legal name at the time. In 1996, I changed my legal name from
`
`John Ridgway to John Ridgway Brady.
`
`- 3 -
`
`
`
`IPR2016-01693
`Declaration of John Ridgway Brady
`
`witness. As a result, the date in the upper left-hand corner of each page is the date
`
`that I performed the experiment recorded on the page.
`
`12.
`
`I kept my laboratory notebooks in the ordinary course of my work as a
`
`research technician with Genentech. I have retained my laboratory notebooks in
`
`my possession in connection with my work at Genentech, except to allow for
`
`filming and/or scanning by Genentech’s records department. Genentech regularly
`
`creates copies of completed notebooks as an additional record of each researcher’s
`
`work. For example, as shown on the covers of my Notebooks 10840 and 11162,
`
`they were both originally filmed on December 23, 1991.
`
`III. My Work on Humanized 4D5 Antibodies
`
`13.
`
`- 4 -
`
`
`
`Declaration of John Ridgway Brady
`
`IPR20l6—01693
`
`14-
`
`15-
`
`
`
`IPR2016-01693
`Declaration of John Ridgway Brady
`
`16.
`
`17.
`
`- 6 -
`
`
`
`IPR2016-01693
`Declaration of John Ridgway Brady
`
`18.
`
`- 7 -
`
`
`
`Declaration of John Ridgway Brady
`
`IPR20l6-01693
`
`19-
`
`20-
`
`
`
`IPR2016-01693
`Declaration of John Ridgway Brady
`
`21.
`
`22.
`
`- 9 -
`
`
`
`Declaration of John Ridgway Brady
`
`IPR20l6-01693
`
`
`
`IPR2016-01693
`Declaration of John Ridgway Brady
`
`24.
`
`- 11 -
`
`
`
`IPR2016-01693
`Declaration of John Ridgway Brady
`
`I declare under penalty of perjury of the laws of the United States of
`
`America that the foregoing is true and correct.
`
`Date: December 5, 2016
`
`- 12 -
`
`